Suryaram Gummuluru | Profiles RNS

Suryaram Gummuluru, PhD

Professor

Boston University Chobanian & Avedisian School of Medicine

Virology, Immunology & Microbiology

PhD, University of Rochester
MS, University of Rochester
BSc, University Saskatchewan

Websites

	Microbiology Faculty
	Immunology Training Program Faculty

ORCID : 0000-0002-8606-8481

Our research is broadly focused on the role of dendritic cells (DCs) in the initiation and propagation of HIV-1 replication. Since dendritic cells are believed to be the first immune competent cells to encounter virus in the genital mucosa, a thorough understanding of the HIV-DC interactions is of paramount importance. DCs can capture virus particles independently of CD4 and co-receptor complexes, and retain them in an infectious state for an extended period of time. These virus-bearing DCs may then facilitate a more efficient spread of virus to replication-permissive CD4+ T cells. Our recent work has identified a novel glycosphingolipid dependent mechanism of virus attachment to DCs. The fate of the virus particle post-attachment in DCs remains unclear. Virion trafficking within the DC bypasses conventional endocytic organelles, i.e., endosomes and lysosomes. Virus localization within this novel vesicular compartment not only has the potential to protect the invading HIV from being degraded, but also creates a latent reservoir of virus, which could present a major challenge for eradication by antiretroviral therapy. Furthermore, the mechanism of subsequent return of infectious virus particles to the cell surface and the method of subsequent transmission to T cells remains unclear. Current studies utilizing biochemical and microscopic approaches are underway to monitor HIV-1 trafficking and localization in the DC and its subsequent transfer to T cells.

Faculty
Boston University
National Emerging Infectious Disease Lab

Member
Boston University
Genome Science Institute

Graduate Faculty (Primary Mentor of Grad Students)
Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences

BU Research
NIH RePORTER Research

Providence/Boston Center for AIDS Research (CFAR): Core Support (Cores A, B, G, K, L, SWG)
07/01/2023 - 06/30/2028 (Co-Investigator of Sub-Project / SP)
The Miriam Hospital NIH NIAID
2P30AI042853-25

Improved Nanoparticle Targeting of Tissue Myeloid Cells for HIV-1 Long-acting Pre-exposure Prophylaxis
03/17/2023 - 02/28/2027 (Multi-PI)
PI: Suryaram Gummuluru, PhD
NIH/National Institute of Allergy & Infectious Diseases
1R01AI175068-01A1

Persistent HIV-1 expression and microglia dysfunction
08/01/2021 - 05/31/2026 (Multi-PI)
PI: Suryaram Gummuluru, PhD
Boston Medical Center Corporation NIH NIDA
5R01DA055488-03

Single Cell Transcriptomics of the Opioid Use Disorder ad HIV Syndemic in the Human Brain
11/05/2020 - 08/31/2025 (Multi-PI)
PI: Suryaram Gummuluru, PhD
J. Craig Venter Institute NIH NIDA
5UM1DA051411-03

Research Training in Immunology
08/24/2020 - 07/31/2025 (PI)
NIH/National Institute of Allergy & Infectious Diseases
5T32AI007309-34

Plasmonic Inactivation of Virus and Mycoplasma Contaminants
08/01/2021 - 05/31/2025 (Multi-PI)
PI: Suryaram Gummuluru, PhD
NIH/National Institute of General Medical Sciences
5R01GM142012-03

Synergistic Mechanisms of chronic Innate Immune Activation in Microglia by opiates and HIV Infection
07/15/2020 - 04/30/2025 (Multi-PI)
PI: Suryaram Gummuluru, PhD
NIH/National Institute on Drug Abuse
5R01DA051889-04

Dual antiretroviral loaded nanoparticles for long-acting suppressive HIV therapy
02/28/2023 - 02/27/2025 (Key Person / Mentor)
NIH/National Institute of Allergy & Infectious Diseases
1F31AI172625-01

Persistent HIV expression induced type 1 IFN responses and inflammaging
08/01/2018 - 04/30/2024 (PI)
NIH/National Institute on Aging
5R01AG060890-05

GM3 Nanoparticles for Sustained Delivery of Anti-Retrovirals to Lymphatic Tissues
11/08/2017 - 10/31/2023 (Multi-PI)
PI: Suryaram Gummuluru, PhD
NIH/National Institute of Allergy & Infectious Diseases
5R01AI132111-05

Showing 10 of 20 results. Show All Results

Title

Yr	Title	Project-Sub Proj
2024	Improved Nanoparticle Targeting of Tissue Myeloid Cells for HIV-1 Long-acting Pre-exposure Prophylaxis	5R01AI175068-02
2023	Improved Nanoparticle Targeting of Tissue Myeloid Cells for HIV-1 Long-acting Pre-exposure Prophylaxis	1R01AI175068-01A1
2023	Plasmonic Inactivation of Virus and Mycoplasma Contaminants	5R01GM142012-03
2023	Persistent HIV-1 expression and microglia dysfunction	5R01DA055488-03
2023	Synergistic Mechanisms of chronic Innate Immune Activation in Microglia by Opiates and HIV Infection	5R01DA051889-04
2023	Research Training in Immunology	5T32AI007309-34
2022	Plasmonic Inactivation of Virus and Mycoplasma Contaminants	5R01GM142012-02
2022	Persistent HIV-1 expression and microglia dysfunction	5R01DA055488-02
2022	Synergistic Mechanisms of chronic Innate Immune Activation in Microglia by Opiates and HIV Infection	5R01DA051889-03
2022	Persistent HIV expression induced type I IFN responses and inflammaging	5R01AG060890-05

Showing 10 of 47 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis Copy PMIDs To Clipboard

Nisa A, Kumar R, Ramasamy S, Kolloli A, Olejnik J, Jalloh S, Gummuluru S, Subbian S, Bushkin Y. Modulations of Homeostatic ACE2, CD147, GRP78 Pathways Correlate with Vascular and Endothelial Performance Markers during Pulmonary SARS-CoV-2 Infection. Cells. 2024 Feb 29; 13(5).View Related Profiles.

Olejnik, Judith
Gummuluru, Suryaram

PMID: 38474396; PMCID: PMC10930588; DOI: 10.3390/cells13050432;

Komori M, Morey AL, Quiñones-Molina AA, Fofana J, Romero L, Peters E, Matsuda K, Gummuluru S, Smith JF, Akahata W, Akiyama H. Incorporation of 5 methylcytidine alleviates innate immune response to self-amplifying RNA vaccine. bioRxiv. 2023 Nov 01.View Related Profiles.

Akiyama, Hisashi
Gummuluru, Suryaram

PMID: 37961509; PMCID: PMC10634970; DOI: 10.1101/2023.11.01.565056;

de Oliveira Junior GP, Welsh JA, Pinckney B, Palu CC, Lu S, Zimmerman A, Barbosa RH, Sahu P, Noshin M, Gummuluru S, Tigges J, Jones JC, Ivanov AR, Ghiran IC. Human red blood cells release microvesicles with distinct sizes and protein composition that alter neutrophil phagocytosis. J Extracell Biol. 2023 Nov; 2(11). PMID: 37942280; PMCID: PMC10629908; DOI: 10.1002/jex2.107;

Tseng AE, Carossino M, Gertje HP, O'Connell AK, Gummuluru S, Kolachalama VB, Balasuriya UBR, Connor JH, Bennett RS, Liu DX, Hensley LE, Crossland NA. Hepatic proinflammatory myeloid phenotypes are a hallmark of Ebola virus Kikwit pathogenesis in rhesus monkeys. Vet Pathol. 2023 Jul; 60(4):473-487.View Related Profiles.

Connor, John
Crossland, Nicholas
Gummuluru, Suryaram
Kolachalama, Vijaya

PMID: 37170900

Zang H, Siddiqui M, Gummuluru S, Wong WW, Reinhard BM. Ganglioside-Functionalized Nanoparticles for Chimeric Antigen Receptor T-Cell Activation at the Immunological Synapse. ACS Nano. 2022 Nov 22; 16(11):18408-18420. PMID: 36282488; PMCID: PMC9815837; DOI: 10.1021/acsnano.2c06516;

Jalloh S, Olejnik J, Berrigan J, Nisa A, Suder EL, Akiyama H, Lei M, Ramaswamy S, Tyagi S, Bushkin Y, Mühlberger E, Gummuluru S. CD169-mediated restrictive SARS-CoV-2 infection of macrophages induces pro-inflammatory responses. PLoS Pathog. 2022 Oct; 18(10):e1010479.View Related Profiles.

Muhlberger, Elke
Akiyama, Hisashi
Olejnik, Judith
Gummuluru, Suryaram

PMID: 36279285; PMCID: PMC9632919; DOI: 10.1371/journal.ppat.1010479;

Boytz R, Slabicki M, Ramaswamy S, Patten JJ, Zou C, Meng C, Hurst BL, Wang J, Nowak RP, Yang PL, Sattler M, Stone RM, Griffin JD, Gray NS, Gummuluru S, Davey RA, Weisberg E. Anti-SARS-CoV-2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID-19 therapy. J Med Virol. 2023 Jan; 95(1):e28157.View Related Profiles.

Davey, Robert
Gummuluru, Suryaram

PMID: 36117402; PMCID: PMC9538324; DOI: 10.1002/jmv.28157;

Patten JJ, Keiser PT, Morselli-Gysi D, Menichetti G, Mori H, Donahue CJ, Gan X, Valle ID, Geoghegan-Barek K, Anantpadma M, Boytz R, Berrigan JL, Stubbs SH, Ayazika T, O'Leary C, Jalloh S, Wagner F, Ayehunie S, Elledge SJ, Anderson D, Loscalzo J, Zitnik M, Gummuluru S, Namchuk MN, Barabási AL, Davey RA. Identification of potent inhibitors of SARS-CoV-2 infection by combined pharmacological evaluation and cellular network prioritization. iScience. 2022 Sep 16; 25(9):104925.View Related Profiles.

Anderson, Deborah
Mori, Hiroyuki
Davey, Robert
Gummuluru, Suryaram

PMID: 35992305; PMCID: PMC9374494; DOI: 10.1016/j.isci.2022.104925;

Jalloh S, Olejnik J, Berrigan J, Nisa A, Suder EL, Akiyama H, Lei M, Tyagi S, Bushkin Y, Mühlberger E, Gummuluru S. CD169-mediated restrictive SARS-CoV-2 infection of macrophages induces pro-inflammatory responses. bioRxiv. 2022 Mar 30.View Related Profiles.

Muhlberger, Elke
Akiyama, Hisashi
Olejnik, Judith
Gummuluru, Suryaram

PMID: 35378756; PMCID: PMC8978933; DOI: 10.1101/2022.03.29.486190;

Zang H, Fofana J, Xu F, Nodder SB, Gummuluru S, Reinhard BM. Characterizing Lipid-Coated Mesoporous Silica Nanoparticles as CD169-Binding Delivery System for Rilpivirine and Cabotegravir. Adv Nanobiomed Res. 2022 May; 2(5). PMID: 36313942; PMCID: PMC9610980; DOI: 10.1002/anbr.202100157;

Showing 10 of 65 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 65 publications over 27 distinct years, with a maximum of 7 publications in 2022